

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Kelsall et al.

Serial No.: 09/196,867

Filed: November 20, 1999

For: METHODS OF USING CR3 AND CR4

> LIGANDS FOR INHIBITING INTERLEUKIN-12 TO TREAT AUTOIMMUNE DISEASE

Group Art Unit: 1642

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C. Suite 1200, The Candler Ruild 127 Peachtree Street, N.E. Atlanta, Georgia 30303-1811

August 18, 2000

Sir:

Submitted herewith on form PTO 1449 is a listing of a document known to applicants and/or their attorneys in compliance with the requirements of 37 C.F.R. § 1.56. Applicants certfy that the cited document was not known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of this statement. A copy of this document is enclosed.

Consideration of the cited document and making the same of record in the prosecution of the above-noted application are respectfully requested.



ATTORNEY DOCKET NO. 14014.0312 Serial No. 09/196,867

It is believed that this paper is being timely filed and that no fee is required for the filing thereof. However, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Mary L. Miller

Registration No. 39,303

NEEDLE & ROSENBERG, P.C. Suite 1200, The Candler Building 127 Peachtree Street, N.E. Atlanta, Georgia 30303-1811 404/688-0770

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on August 18, 2000.

Mary L. Miller

<u>Queust 18, 2000</u>